Pan-cancer and single-cell analysis reveal the prognostic value and immune response of NQO1.

Overexpression of the gene has been linked with tumor progression, aggressiveness, drug resistance, and poor patient prognosis. Most research has described the biological function of the in certain types and limited samples, but a comprehensive understanding of the 's function and clinical importance at the pan-cancer level is scarce. More research is needed to understand the role of in tumor infiltration, and immune checkpoint inhibitors in various cancers are needed. The expression data for 33 types of pan-cancer and their association with the prognosis, pathologic stage, gender, immune cell infiltration, the tumor mutation burden, microsatellite instability, immune checkpoints, enrichment pathways, and the half-maximal inhibitory concentration (IC50) were downloaded from public databases. Our findings indicate that the gene was significantly upregulated in most cancer types. The Cox regression analysis showed that overexpression of the gene was related to poor OS in Glioma, uveal melanoma, head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma, and adrenocortical carcinoma. mRNA expression positively correlated with infiltrating immune cells and checkpoint molecule levels. The single-cell analysis revealed a potential relationship between the mRNA expression levels and the infiltration of immune cells and stromal cells in bladder urothelial carcinoma, invasive breast carcinoma, and colorectal cancer. Conversely, a negative association was noted between various drugs (17-AAG, Lapatinib, Trametinib, PD-0325901) and the mRNA expression levels. NQO1 expression was significantly associated with prognosis, immune infiltrates, and drug resistance in multiple cancer types. The inhibition of the -dependent signaling pathways may provide a promising strategy for developing new cancer-targeted therapies.